mulpleo (previously lusutrombopag shionogi)
shionogi b.v. - lusutrombopag - trombocitopenija - antihemoragije - mulpleo je primerna za zdravljenje hude trombocitopenije pri odraslih bolnikih s kronično bolezen jeter, ki opravljajo invazivnih postopkov,.
furosoral 10 mg tbl
le vet -
furosoral 40mg tbl
le vet -
doptelet
swedish orphan biovitrum ab (publ) - avatrombopag maleate - trombocitopenija - antihemoragije - doptelet je primerna za zdravljenje hude trombocitopenije pri odraslih bolnikih s kronično bolezen jeter, ki so načrtovani, da opravijo invaziven postopek. doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (itp) in adult patients who are refractory to other treatments (e. kortikosteroidi, imunoglobulini).
pemetreksed sandoz 25 mg/ml koncentrat za raztopino za infundiranje
pemetreksed - koncentrat za raztopino za infundiranje - pemetreksed 25 mg / 1 ml - pemetreksed
pemetreksed sandoz 25 mg/ml koncentrat za raztopino za infundiranje
pemetreksed - koncentrat za raztopino za infundiranje - pemetreksed 25 mg / 1 ml - pemetreksed
pemetreksed sandoz 25 mg/ml koncentrat za raztopino za infundiranje
pemetreksed - koncentrat za raztopino za infundiranje - pemetreksed 25 mg / 1 ml - pemetreksed
pemetreksed ever pharma 25 mg/ml koncentrat za raztopino za infundiranje
pemetreksed - koncentrat za raztopino za infundiranje - pemetreksed 25 mg / 1 ml - pemetreksed
pemetreksed tad 100 mg prašek za koncentrat za raztopino za infundiranje
pemetreksed - prašek za koncentrat za raztopino za infundiranje - pemetreksed 100 mg / 1 viala - pemetreksed
pemetrexed baxter
baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastična sredstva - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5. pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5. pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.